United States Food and Drug Administration
Sanofi’s Altuviiio closing in on blockbuster status, Dupixent sales surge
Altuviiio, Sales – occupational activity, sanofi, Dupixent, United States Food and Drug Administration
Vanda Escalates Vendetta Against FDA, Blasts Bureaucrats for Delaying Stomach Drug
United States Food and Drug Administration, Vanda, United States Food and Drug Administration, Gastroparesis, Translucent
Novavax’s COVID-19 jab looks to be on track for approval
Vaccines, COVID19 (disease), United States Food and Drug Administration, Approved, Novavax, Novavax ‘s, Novavax
Facing added pressure from Eli Lilly, Novo Nordisk submits for FDA approval of oral GLP-1 obesity drug
Nordisk, Obesity, Approved, Oral cavity, Glucagon-Like Peptide 1, Market, Pressure- physical agent, eli lilly, competition, Novo, semaglutide, United States Food and Drug Administration, United States Food and Drug Administration
Dupixent notches seventh disease approval with urticaria nod
Dupixent, Chronic Spontaneous Urticaria, Approved, Urticaria, United States Food and Drug Administration, seventh
Chinese CRO GemPharmatech expands in San Diego as industry weighs FDA’s animal testing shift
United States Food and Drug Administration, GemPharmatech, Contract Research Organization, San Diego, Animal Testing, mouse models, expansion, Industry
FDA rejection of extended dosing interval is another piece of bad news for Regenerons Eylea HD
United States Food and Drug Administration, Interval, Regeneron, dosing, Extension, Eylea HD, rejection, Age related macular degeneration, Diabetic Retinopathy
FDA moves to block biopharma employees from serving on advisory committees
United States Food and Drug Administration, Workers, Advisory Committees, Industry, Policy
RFK Jr.’s FDA staff cuts claimed key user fee negotiators, threatening renewal talks with pharma: Reuters
United States Food and Drug Administration, Does speak, Staff, negotiators, HHS, Mediation, user fee, Fees, Drug Industry
FDA clears its first prescription migraine app, from Click Therapeutics
United States Food and Drug Administration, CT-132, Migraine Disorders, Click Therapeutics, click, first